Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has rescheduled its third quarter 2024 financial results announcement to November 13, 2024. The date change accommodates SEC filing rules affected by the November 11 federal holiday. The company will host a webcast at 8:30 a.m. Eastern Time to discuss results and provide a corporate update. The webcast will be accessible on Liquidia's website and archived for one year.
Liquidia (NASDAQ: LQDA), un'azienda biofarmaceutica concentrata sulle terapie per malattie cardiopolmonari rare, ha riprogrammato l'annuncio dei suoi risultati finanziari del terzo trimestre del 2024 al 13 novembre 2024. Il cambiamento di data è stato effettuato per conformarsi alle regole di registrazione della SEC, influenzate dalla festività federale dell'11 novembre. L'azienda ospiterà un webcast alle 8:30 ora orientale per discutere i risultati e fornire un aggiornamento aziendale. Il webcast sarà accessibile sul sito web di Liquidia e archiviato per un anno.
Liquidia (NASDAQ: LQDA), una empresa biofarmacéutica enfocada en terapias para enfermedades cardiopulmonares raras, ha reprogramado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el 13 de noviembre de 2024. El cambio de fecha se realiza para cumplir con las reglas de presentación de la SEC afectadas por el feriado federal del 11 de noviembre. La empresa llevará a cabo un webcast a las 8:30 a.m. hora del Este para discutir los resultados y proporcionar una actualización corporativa. El webcast será accesible en el sitio web de Liquidia y estará archivado durante un año.
Liquidia (NASDAQ: LQDA)는 희귀 심폐 질환 치료에 집중하는 생명공학 회사로, 2024년 3분기 재무 결과 발표를 2024년 11월 13일로 재조정했습니다. 날짜 변경은 11월 11일 연방 공휴일로 영향을 받은 SEC 제출 규정을 반영하기 위해 이루어졌습니다. 회사는 동부 표준시로 오전 8시 30분에 결과를 논의하고 기업 업데이트를 제공하는 웨비니를 개최할 예정입니다. 웨비니는 Liquidia의 웹사이트에서 접근 가능하며 1년 동안 아카이브됩니다.
Liquidia (NASDAQ: LQDA), une entreprise biopharmaceutique axée sur les thérapies pour les maladies cardiopulmonaires rares, a reporté l'annonce de ses résultats financiers du troisième trimestre 2024 au 13 novembre 2024. Ce changement de date a été effectué pour se conformer aux règles de dépôt de la SEC, affectées par le jour férié fédéral du 11 novembre. L'entreprise animera un webcast à 8h30, heure de l'Est, pour discuter des résultats et fournir une mise à jour de l'entreprise. Le webcast sera accessible sur le site web de Liquidia et archivé pendant un an.
Liquidia (NASDAQ: LQDA), ein biopharmazeutisches Unternehmen, das sich auf Therapien für seltene Herz-Lungen-Erkrankungen konzentriert, hat die Bekanntgabe seiner finanziellen Ergebnisse für das 3. Quartal 2024 auf den 13. November 2024 verschoben. Die Datumsänderung wurde vorgenommen, um den SEC-Einreichungsregeln Rechnung zu tragen, die durch den Bundesfeiertag am 11. November betroffen sind. Das Unternehmen wird um 8:30 Uhr Eastern Time ein Webcast veranstalten, um die Ergebnisse zu diskutieren und ein Unternehmensupdate zu geben. Der Webcast wird auf der Website von Liquidia zugänglich sein und ein Jahr lang archiviert werden.
- None.
- None.
MORRISVILLE, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today it will now report its third quarter 2024 financial results on Wednesday, November 13, 2024. The date has been moved to accommodate for SEC filing rules impacted by the federal holiday observed on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When will Liquidia (LQDA) report Q3 2024 earnings?
What time is Liquidia's (LQDA) Q3 2024 earnings call?
Why did Liquidia (LQDA) change its Q3 2024 earnings report date?
Where can I access Liquidia's (LQDA) Q3 2024 earnings webcast?
